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Abstract
Background: In early-stage breast cancer, the cornerstone of treatment is surgery. After breast-conserving surgery,
adjuvant radiotherapy has shown to improve locoregional control and overall survival rates. The use of breast
radiotherapy in the preoperative (preop) setting is far less common. Nevertheless, it might improve disease-free
survival as compared to postoperative radiotherapy. There is also a possibility of downsizing the tumour which
might lead to a lower need for mastectomy. There are some obstacles that complicate its introduction into daily
practice. It may complicate surgery or lead to an increase in wound complications or delayed wound healing.
Another fear of preop radiotherapy is delaying surgery for too long. At Ghent University Hospital, we have
experience with a 5-fraction radiotherapy schedule allowing radiotherapy delivery in a very short time span.
Methods: Twenty female breast cancer patients with non-metastatic disease receiving preop chemotherapy will be
randomized between preop or postoperative radiotherapy. The feasibility of preop radiotherapy will be evaluated
based on overall treatment time. All patients will be treated in 5 fractions of 5.7 Gy to the whole breast with a
simultaneous integrated boost to the tumour/tumour bed of 5 × 6.2 Gy. In case of lymph node irradiation, the
lymph node regions will receive a dose of 27 Gy in 5 fractions of 5.4 Gy. The total duration of therapy will be 10 to
12 days. In the preop group, overall treatment time is defined as the time between diagnosis and the day of last
surgery, in the postop group between diagnosis and last irradiation fraction. Toxicity related to surgery, radio-, and
chemotherapy will be evaluated on dedicated case-report forms at predefined time points. Tumour response will
be evaluated on the pathology report and on MRI at baseline and in the interval between chemotherapy and
surgery.
Discussion: The primary objective of the trial is to investigate the feasibility of preop radiotherapy. Secondary
objectives are to search for biomarkers of response and toxicity and identify the involved cell death mechanisms
and the effect of preop breast radiotherapy on the in-situ immune micro-environment.
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Background
In early-stage breast cancer, the cornerstone of treat-
ment is surgery: either mastectomy (ME) or breast-
conserving surgery (BCS). After surgery, most patients
receive some kind of adjuvant systemic therapy such as
hormone therapy, chemotherapy (CT), targeted therapy,
or a combination of these. After BCS, adjuvant radio-
therapy (RT) has shown to improve locoregional control
and overall survival rates. After ME, a benefit of adjuvant
RT was observed only in node positive patients [1, 2]. In
recent years, adjuvant or postoperative (postop) CT is
increasingly replaced by preoperative (preop) or neo-
adjuvant CT in patients with larger tumours to avoid
mastectomy or tumours with a more aggressive pheno-
type (triple negative or HER2 amplified cancers) for early
response assessment [3, 4]. Several randomized con-
trolled trials demonstrated that there is no difference in
overall survival whether CT is given pre- or postopera-
tively [5, 6].
The use of breast RT in the preop setting is far less
common. It has been proposed for patients with inoper-
able or inflammatory breast cancer, and a recent retro-
spective study in breast cancer patients showed preop
RT might improve disease-free survival as compared to
postop RT [7]. In another retrospective study comparing
preop versus postop radio- and chemotherapy, a possible
benefit of preop treatment was suggested for tumours
larger than 2 cm [8]. These benefits have also been ob-
served in other cancer sites. There is evidence from ran-
domized trials that preop RT is more effective than
postop RT in patients with rectal carcinoma [9]. For soft
tissue sarcoma, better local control rates have been de-
scribed with preop than with postop RT [10]. From a
radiobiological point of view, the benefits of giving RT
preoperatively are obvious. In contrast to the postop set-
ting, the vasculature is still intact and less radio-resistant
tumour clones are present, both possibly increasing ra-
diosensitivity. But there are other advantages of preop
RT treatment such as improved delineation of the
tumour and peritumoural bed for RT planning, which is
evidently easier with the tumour still in place. In the
postop setting, unnecessary larger volumes are delin-
eated [11] and interobserver variability is larger [12] than
in the preop setting. In preop RT, regions in need of
higher doses can be better targeted. For the latter rea-
son, less acute side effects and a better overall breast
cosmesis is expected. There is also a possibility of down-
sizing the tumour which might lead to a lower need for
mastectomy. While preop breast RT clearly has some
advantages, there are some obstacles that complicate its
introduction into daily practice. Preop RT therapy may
complicate surgery or lead to an increase in postop
wound complications or delayed wound healing.
Whereas delayed wound healing compromises overall
treatment time if adjuvant treatment is delivered postop-
eratively, this is not the case for preop chemo and
radiotherapy.
Another fear of preop RT is delaying surgery and/or
CT for too long, thus increasing the risk of distant me-
tastases. However, this is not an issue if radiation
courses are short. At Ghent University Hospital, we have
experience with a 5-fraction RT schedule [13] allowing
preop RT delivery in a very short time span. Large ran-
domized trials confirm that moderate hypofractionation
schemes in 15 or 16 fractions are at least equivalent in
tumour control and toxicity although the biological
equivalent total dose is lower than the traditional 50 Gy
in 25 fractions [14–16]. Further acceleration to 5 frac-
tions is expected to have an even greater radiobiological
advantage concerning tumour control. In the UK FAST
randomized trial, a schedule of 5 times 5.7 Gy, once a
week, was compared to a normofractionation schedule
of 25 times 2 Gy. Tumour control and toxicity were
comparable after 3 and 8 years of follow-up [17]. In the
UK Fast-Forward trial, a once-weekly 5-fraction schedule
is studied. It may be considered for patients in whom a
daily visit for 3 or 5 weeks is not acceptable however
careful consideration of the dose per fraction is required
[18]. At Ghent University Hospital (UZ Gent), a feasibil-
ity trial was started using the FAST scheme (5 × 5.7 Gy)
over 12 days (instead of 5 weeks) in patients of 65 years
or older. Additionally, patients requiring a boost re-
ceived a simultaneously integrated boost to the tumour
bed of 5 × 6.5 Gy. The final analysis on 95 patients
shows < 10% grade 2–3 erythema, with only one case of
moist desquamation, located at a skin fold [13]. With
this RT schedule of 5 fractions in 12 days given pre-
operatively, we hypothesize that overall treatment time
will not be increased.
Since the tumour is still present in preop RT, this pre-
sents a unique opportunity to identify the involved cell
death mechanisms of breast RT. Classically, RT is con-
sidered to mediate its effects via the direct killing of can-
cer cells. It is now known that RT can induce systemic
effects resulting in tumour responses outside the irradi-
ated regions [19]. This phenomenon called the “absco-
pal”-effect has been reported in breast cancer [20] and
several other kinds of malignancies [21] and is nowadays
considered to be immune-mediated [22]. The hypothesis
is that RT induces immunogenic cell death (ICD)
through the release of tumour-associated antigens and
damage associated molecular patterns (DAMPs), which
leads to antigen uptake and dendritic cell maturation,
resulting in the priming and clonal expansion of cyto-
toxic T-lymphocytes (CTLs) in the lymph nodes [23].
These CTLs then travel back to the tumour, becoming
tumour-infiltrating lymphocytes (TILs). Radiation could
increase these TILs in a clinical setting [24, 25] and,
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more importantly, a high level of (post-therapy) TILs is
associated with a good prognosis [25–29]. Immunogenic
cell death implicates the release of DAMPs and
tumoural antigens through a disintegrated cell plasma
membrane. The latter correlates with necrosis (regulated
or secondary) instead of apoptosis, which was considered
to be the principal mechanism of radiation induced cell
death for years [30, 31]. Distinct cell death modalities
may thus have a different (immunogenic) outcome.
Additional to the immunogenic cell death mechanism,
this study will also investigate extracellular vesicles (EVs)
as biomarkers for response and toxicity. EVs are
nanometer-sized membrane vesicles that contain lipids,
proteins, nucleic acids, and metabolites. Different cell
types can release EV, including immune cells (mono-
cytes, neutrophils, etc.), tumour cells, fibroblasts, and ad-
ipocytes (fat cells) [32, 33]. Extracellular vesicles are
promising novel biomarkers because (1) their molecular
content is a fingerprint of the releasing cells and their
status and consists of proteins, lipids, and nucleic acids,
(2) they are released in easily accessible body fluids such
as blood, and (3) they are enriched for highly selected
biomarkers which otherwise would constitute only a very
small proportion (less than 0.01%) of the total molecular
content of blood [34]. Analysis of Glypican-1 positive
EV in circulation distinguishes with absolute specificity
and sensitivity healthy subjects and patients with a be-
nign pancreatic disease from patients with early- and
late-stage pancreatic cancer [35, 36] and non-pancreatic
cancer [37]. EV transfer from stromal to breast cancer
cells regulates therapy resistance pathways [38]. miRNA
levels in circulating EV identify remnant vital tumour
tissue and are suitable to measure therapy response and
relapse monitoring [39]. These pioneering studies sug-
gest that quantification and characterization of EV can
be implemented to predict therapy response.
Methods
Objectives
The primary objective of the trial is to investigate the
feasibility of preop breast RT. Secondary objectives are
to search for biomarkers of response and toxicity and
identify the involved cell death mechanisms and the ef-
fect of preop breast RT on the in-situ immune micro-
environment. The feasibility of preop RT will be assessed
in terms of overall treatment time and toxicity related to
surgery, CT, and RT. In the preoperative group, overall
treatment time is defined as the time between diagnosis
and the day of last surgery, in the postoperative group
the time between diagnosis and last dose of RT. Second-
ary endpoints are the tumour response rate, the rate of
mastectomy, identification of biomarkers of response
and toxicity on EVs from plasma, immunohistochemis-
try of cell death markers and TILs on pre-treatment,
post-RT as well as tumourectomy tissue samples, cardiac
toxicity, lung function, and quality of life.
Study population
Twenty patients will be randomized between preop or
postop RT as illustrated in Fig. 1. Inclusion criteria are
female patients with non-metastasized breast cancer, for
which a multidisciplinary decision must be made for
preop CT, either this is for downsizing locally advanced
breast cancer of because of type of tumour, such as
triple-negative or HER2-positive early-stage breast can-
cer. Adjuvant hormone therapy will be administered to
eligible women. For each patient, a biopsy with tumour
histology, histological grade, ER/PR status, Her2/Neu
status (amplification or not), and Ki67 status will be
available. Exclusion criteria are distant metastases, in-
flammatory breast cancer (mastitis carcinomatosa),
multifocal tumour, lobular carcinoma, bilateral breast
cancer, history of cancer, with the exception of non-
melanoma skin cancer, in situ cervix carcinoma, history
of chemotherapy, history of radiation treatment, preg-
nant or breast feeding, or not using contraceptives if in
reproductive age category, planned immediate recon-
structive surgery, conditions making toxicity evaluation
difficult (e.g. skin disorders), and amioderone treatment
in the last 6 months. Exceptions to excluded carcinomas
are made because these carcinomas occur frequently and
result in a better life expectancy, so there is limited
interference with the current study. There are also spe-
cial exclusion criteria in function of chemotherapy, such
as less than 2500 leukocytes or less than 1000/μL abso-
lute neutrophil count.
In patients with clinically suspicious axillary lymph
nodes a fine needle aspiration for cytology (FNAC) will
be performed. If lymph node involvement is confirmed
by FNAC, they will receive an axillary clearance after
neoadjuvant treatment and axillary RT will be performed
(either preop or postop). In clinically node-negative pa-
tients with a tumour of ≤ 5 cm, a sentinel node biopsy
will be performed before the start of RT or CT. Patients
with a tumour of > 5 cm, clinically node negative, will
receive axillary clearance and axillary RT since a sentinel
node biopsy is less reliable in these large tumours. Pa-
tients receiving postop RT will receive neoadjuvant CT
followed by surgery (21–28 days after CT) and adjuvant
RT starting 28–35 days after surgery. Patients receiving
preop RT will receive RT first, followed by CT (5–8 days
after the end of RT) and surgery (21–28 days after CT).
In all patients, a marker clip will be placed in the
tumour to determine its location before the start of any
treatment. Ethics approval has received (EC2018/0599)
and the study is registered at clinicaltrials.gov
(NCT03783364).
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Treatment
Patients will be treated with 4 cycles of epirubicin and
cyclophosphamide either in a dose dense scheme every 2
weeks or in a non-dose dense scheme every 3 weeks,
followed by 12 weeks of paclitaxel. The 2 type of dura-
tions in chemotherapy makes the comparison of dur-
ation of treatment difficult, only the delay in treatment
will be measured and not the normal duration of sys-
temic therapy. For Her2 amplified tumours, trastuzumab
will be added to the treatment concomitant with pacli-
taxel, every 3 weeks for a total of 18 cycles.
All patients will be treated according to routine prac-
tice at Ghent University Hospital. If lymph node irradi-
ation is not indicated (i.e. patients with a negative
sentinel node procedure), patients will be treated in the
prone position if possible [40–42]. All other patients will
receive treatment in the supine position. Left-sided
breast cancer patients treated in the prone position will
undergo two simulation CT’s: shallow breathing and
deep inspirational breath hold (DIBH). This is a
technique used to reduce heart dose by increasing the
distance between the treated breast and the heart. Pa-
tients are asked to take a deep breath and block inspir-
ation for a limited time span during which radiation is
delivered. Only when the mean heart dose exceeds 0.73
Gy will the technique be used for radiation delivery. In
all other cases, treatment will be delivered during shal-
low breathing [43]. All patients will be treated in 5 frac-
tions of 5.7 Gy to the whole breast with a simultaneous
integrated boost (SIB) to the tumour/tumour bed of 5 ×
6.2 Gy. In case of lymph node irradiation, the lymph
node regions will receive a dose of 27 Gy in 5 fractions
of 5.4 Gy. Radiotherapy will be performed every other
day, thus permitting cell repair in between fractions. The
total duration of therapy will be 10–12 days. The whole
breast and lymph node regions (in case of lymph node
irradiation) are delineated based on the ESTRO/PRO-
CAB guidelines [44]. The heart is delineated based on
the guidelines provided by Feng et al. [45]. In the preop
radiotherapy group, gross tumour volume (GTV) is
Fig. 1 Flow chart
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delineated on the CT-simulation scan with guidance of
MRI. The clinical target volume for boost irradiation
(CTV_boost) includes the GTV with a margin of 5 mm
around the GTV. Around the CTV, a planning target
volume for the SIB (PTV_boost) is created by adding a
margin of 5 mm. A median dose of 31 Gy (5 × 6.2 Gy) is
prescribed to the PTV_boost with a dose fall off region
of 1.5 cm around this PTV_boost, not extending outside
the breast. The dose fall off region receives a minimum
dose of 27.08 Gy with 95% receiving at least 27.9 Gy. In
the postop radiotherapy group, CTV_boost will be delin-
eated based on the surgical clips, the histology report,
and all available pre-operative information (clinical in-
vestigation, imaging). Around the CTV_boost, a dose fall
off region of 2 cm is defined. The dose fall off region re-
ceives a minimum dose of 27.08 Gy with 95% receiving
at least 27.9 Gy.
Evaluation of endpoints
The feasibility of preop RT will be evaluated based on
overall treatment time. From a clinical point of view, it
is not warranted that preop RT leads to an increase in
the overall treatment time, since this may compromise
locoregional control and survival. However, it is assumed
that preop RT will shorten the overall treatment time by
about 14 days (SD 9days) since the interval between RT
and CT is shortened considerably. A difference of less
than 14 days is not considered clinically relevant.
As a start point for measuring the overall treatment
time, diagnosis of breast cancer by biopsy is taken, while
delays in treatment by decision-making can be taken in
account. In the preop group, overall treatment time is
defined as the time between diagnosis (biopsy) and the
day of last surgery. In the postop group, overall treat-
ment time is defined as the time between diagnosis (bi-
opsy) and the last day of RT. Toxicity related to surgery,
RT, and CT will be evaluated on dedicated case-report
forms (in Appendix) at predefined time points as illus-
trated in Fig. 2. Tumour response will be evaluated on
the pathology report (complete response rate and Pinder
regression score) and on MRI at baseline and in the
interval between CT and surgery.
To determine the mode of cell death evoked by pre-
operative RT and its effect on the in situ immune micro-
environment measurement (by immunohistochemistry
(IHC)) of cell death markers and TILs will be performed
on pre-treatment, post-RT (only in case of pre-operative
RT), as well as tumourectomy tissue samples. The re-
sults of the IHC stainings for cell death markers will be
correlated with the presence (or increase) of TILs in the
same tissue samples and response to treatment.
All IHC stainings (cell death markers and TILs) will be
performed on consecutive 3.5 μm slides of a representa-
tive formalin-fixed paraffin-embedded tissue block. A
representative tissue block will be selected, taking into
account the cellularity of the remaining tumour after RT
(tissue biopsy after pre-operative RT), CT (tumourect-
omy post-op RT arm), or the combination of both
(tumourectomy specimen pre-operative RT-arm). If re-
sidual tumour cells are absent, a tissue block with
Fig. 2 Study time table
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reactive changes (fibrosis, infiltration by foamy macrophages)
will be selected. The following cell death markers will be ex-
amined: calreticulin (CRT), mobility group box 1 protein
(HMGB-1), and Heat-Shock-Protein 70 (HSP70) for ICD;
Cytokeratine 18 and caspase-3 for apoptosis; Senescense-
associated β-galactosidase for senescence; phosphorylated
mixed lineage kinase domain-like protein (pMLKL), and
receptor-interacting protein kinase 3 (RIP3) for necroptosis
and gluthatione peroxidase-4 (GPX-4) for ferroptosis.
HRQoL will be collected prospectively using different
HRQoL instruments. For our analyses, only the items likely
to be influenced by breast RT will be analysed. The European
Organisation for Research and Treatment of Cancer
(EORTC) 30-item Quality of Life Questionnaire (QLQ-C30)
will be used, complemented by the breast cancer-specific
module (QLQ-BR23). The EORTC QLC-C30 is a cancer-
specific measuring instrument that describes five functional
scales, three symptoms scales, six single-items scales, and a
global health scale. Of these, we selected 2 functional scales
(physical and social functioning), 2 symptoms scales (fatigue
and pain) and the global health scale [46]. The EORTC
QLQ-BR23, consists of 23 items, of which we included 2
symptom scales (i.e. arm symptoms and breast symptoms)
and one functional scale (i.e. future perspective )[47]. The
third questionnaire, the BREAST-Q questionnaire, was de-
signed to evaluate outcome among women undergoing dif-
ferent types of breast surgery [48]. Breast satisfaction and
physical well-being of the breast will be measured with re-
spectively 6 and 7 questions. All questions of the BREAST-Q
questionnaire will be used in this analysis. For all three ques-
tionnaires, a higher score indicates a better functioning for
functional scales, while a higher score for symptom scales in-
dicates a higher level of symptoms. The 3 questionnaires will
be completed by the patient at 3 time points: before start of
RT, 2 to 4 weeks after RT and 1 year after RT.
Sample size and statistical analysis
While reduction of overall treatment time is the primary
end point, sample size is made for this item. With 20 pa-
tients (10 patients in every treatment arm), a 14-day dif-
ference in overall treatment time can be detected with a
power of > 90% (2-sided t test, α = 0.05).
The statistical package SPSS version 26 will be used to
analyse the data. RT-related toxicity will be defined as
any baseline toxicity that deteriorated during or after RT
and any toxicity that arose during or after RT and was
not present at baseline. A clinically relevant deterior-
ation of HRQoL will be defined as a difference in score
between baseline and 2–4 weeks after RT of 10 points or
more. Differences in RT-related toxicity and clinically
relevant deterioration of HRQoL between groups will be
analysed by performing a chi-square test with a signifi-
cance level of p < 0.05. For HRQoL, statistical differ-
ences between baseline scores and scores after 2 to 4
weeks will be evaluated with the Mann–Whitney U test.
Due to the multiple tests for HRQoL, the Bonferroni
correction will be used to avoid type I errors which leads
to an adjusted p value of p < 0.005. 95% confidence in-
tervals will be calculated. Ethics approval is received by
the ethical board of University Hospital Ghent.
Analysis of tissue and liquid biopsies
The results of the IHC stainings for these cell death
markers will be correlated with profiles of CD8, CD4,
CD3, CD68, and FOXP3 TILs (and the change in their
presence after RT, CT or the combination of both). Pa-
tients will be divided into a high- and low-TIL group ac-
cording to international guidelines.
Clinical (MRI) and pathological response assessed ac-
cording to the Pinder regression grade (microscopic ver-
sus macroscopic disease)
Liquid biopsies (plasma samples) will be collected at
consecutive time points (cfr. Fig. 2) to search for EV-
associated biomarkers of response and toxicity. Blood will
be collected in citrate tubes and platelet free plasma (PFP)
will be prepared (2 × 2500×g centrifugation for 15 ) within
1 h after blood collection and stored at – 80 °C. EV will be
isolated and characterized in compliance with MISE
V2018, EV-TRACK, and Coumans et al. [49]. Chromato-
graphic approaches will be combined with density gradi-
ent centrifugation to separate EV in two dimensions, size,
and density, from contaminants such as lipoproteins,
Argonaute-2 protein-miRNA complexes, and protein ag-
gregates [50, 51]. Standard operating procedures have
been optimized to enrich plasma EVs, to extract proteins/
RNA, and to perform proteomics/small RNA sequencing.
Currently, EVs from 6 ml of plasma allows to perform es-
sential quality control experiments combined with proteo-
mics and RNA sequencing [52]. Blood will be collected in
citrate tubes and platelet free plasma (PFP) will be pre-
pared (2 × 2500×g centrifugation for 15 min) within 1 h
after blood collection and stored at – 80 °C. EVs will be
isolated following SOPs, EV will be quantified by nanopar-
ticle tracking analysis (NTA) and analysed by label-free
mass spectrometry and RNA sequencing. We will imple-
ment receiver operating characteristics (ROC) to illustrate
the performance of a biomarker, the sensitivity versus spe-
cificity, and will allow the selection of possible optimal EV
biomarkers (number of EV and/or protein content and/or
RNA content of EV). Advanced data analysis methods
such as Perseus software [53] will further be used to en-
able comparison of expression levels within treatment
groups and between treatment groups.
Discussion
All types of treatment have an influence on general health-
related quality of life [54]. A larger decrease in HRQoL due
to RT is seen if patients started chemotherapy before or
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during RT [55–57]. As well as length of illness and treatment
duration affect HRQoL negatively [58]. By integrating the
boost and an accelerated RT in 5 fractions, overall treatment
time can be reduced, with less acute [59] and 2 years toxicity
[60] and better health-related quality of life [61]. Preop RT
may reduce the overall treatment time with 2 weeks, which
can lead to better quality of life for patients.
Supplementary information
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1186/s40814-020-00693-z.
Additional file 1. Pre or postoperative accelerated radiotherapy (POP-
ART)
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